Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Y-mAbs Therapeutics Inc YMAB

Healthcare Biotechnology
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product... see more

Recent & Breaking News (NDAQ:YMAB)

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Y-mAbs Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Business Wire October 26, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMAB

PR Newswire October 19, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMAB

Newsfile October 16, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMAB

PR Newswire October 10, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMAB

Newsfile October 8, 2022

Y-mAbs Announces Pivotal Data for Omburtamab

GlobeNewswire October 3, 2022

Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil

GlobeNewswire September 26, 2022

Y-mAbs Announces Scheduling of FDA Advisory Committee Meeting for Omburtamab

GlobeNewswire September 1, 2022

Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma

GlobeNewswire August 30, 2022

Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments

GlobeNewswire August 8, 2022

Y-mAbs to Announce Second Quarter 2022 Financial and Operating Results on August 8, 2022

GlobeNewswire August 2, 2022

Y-mAbs' Announces Clearance of IND for GD2-SADA

GlobeNewswire July 12, 2022

Y-mAbs Announces FDA Acceptance of Biologics License Application for OMBLASTYS® (omburtamab) for the Treatment of Neuroblastoma for Priority Review

GlobeNewswire May 31, 2022

Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary Endpoint

GlobeNewswire May 26, 2022

Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments

GlobeNewswire May 9, 2022

Y-mAbs to Announce First Quarter 2022 Financial and Operating Results on May 9, 2022

GlobeNewswire May 3, 2022

Y-mAbs Announces Executive Management Changes and Provides 2022 Revenue Guidance and Financial Update

GlobeNewswire April 27, 2022

Y-mAbs Announces Presentation of SADA Technology at AACR

GlobeNewswire April 8, 2022

Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA

GlobeNewswire April 1, 2022

Moore Kuehn, PLLC Encourages Investors of Y-mAbs Therapeutics, Inc. to Contact Law Firm

Newsfile March 17, 2022